



### EHA&EuroBloodNet Spotlight on Castleman Disease Session 1: Overview on Castleman Disease

Kai Hübel

Elena Sabatini

University of Cologne

AOU Bologna





Hematological

Diseases (ERN EuroBloodNet)

Network





25th of January 2022 No 1: Overview on CD Kai Hübel & Elena Sabatini

- Introduction, History
- Classification
- Pathology
- Diagnosis

### 15th of February 2022 No 3: Idiopathic multicentric CD Simone Ferrero

- Clinical Phenotypes
- Differential diagnosis
- Relationship with TAFRO, IgG4RD, POEMS
- Pathophysiology
- Treatment



 Network Hematological Diseases (ERN EuroBloodNet)

Network for rare or low prevalence complex diseases



1st of February 2022 **No 2: Unicentric CD** Eric Oksenhendler

- Imaging (cases)
- Diagnosis, initial Assessment
- Pathophysiology
- Treatment

#### 8th of March 2022 No 4: KSHV/HHV8 associated multicentric CD Mark Bower & David Boutboul

- Diagnosis
- Complications
- Pathophysiology
- Treatment





- $\checkmark$  30-35min presentation + 15 min Q&A session
- $\checkmark$  Microphones will be muted by host to avoid back noise
- $\checkmark$  Please, stop your video to improve internet connexion
- $\checkmark$  Send your questions during the presentation through the chat, they will be

gathered and answered after the presentations.









- 1. To raise awareness of Casteleman disease
- 2. To emphasise the morbidity and mortality risk of undetected Castleman disease
- 3. To provide an overview on general aspects of pathology and diagnostics









**Conflicts of interest Kai Hübel** 

- Advisory board: Roche, Celgene/BMS, Incyte, EUSA Pharma, and Gilead
- Honoraria: Roche, Celgene/BMS, Servier, EUSA Pharma, Novartis, and Hexal
- Research funding: Roche, Celgene/BMS, Servier, and Janssen

### **Conflicts of interest Elena Sabattini**

- Advisory board: EUSA Pharma
- Honoraria: EUSA Pharma, Novartis











Case records of the Massachusetts General Hospital: Case No. 40231 B CASTLEMAN, V W TOWNE

"peculiar form of lymph-node hyperplasia resembling thymoma"



Bildquelle: Massachusetts General Hospital



 Network Hematological Diseases (ERN EuroBloodNet)

**Network** for rare or low prevalence complex diseases







- 1954 Localized mediastinal lymph node enlargement characterized by increased numbers of lymphoid follicles with germinal center involution and marked capillary proliferation
- 1969 Description of the plasma cell, the hyalinized and the mixed histopathological variants
- 1983 Division into unicentric CD and multicentric CD
- 1985 Description of the association between HIV and CD, followed by the description of the cooccurrence with and overlap between POEMS syndrome and MCD
- 1990s Identification of HHV8 as the etiological driver of all HIV+ and some HIV- MCD cases
- 2010 First description of the "TAFRO" syndrome









- Castleman disease represents a cluster of disorders, encompassing the fields of hematology, immunology, oncology, rheumatology, and virology.
- This heterogeneous group of disorders is characterized by shared histological features
- There are different clinical subtypes dependent on the localisation of the CD and the underlying aetiology:

**Unicentric CD** 


**Multicentric CD** 












**Proportion of iMCD Cases** 



iMCD accounts for **33% – 58%** of all MCD cases

Mukherjee S et al. Oral presentation at the virtual 62<sup>nd</sup> American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020.


van Rhee F, et al. Blood. 2018;132(20):2115-2124.











1. Fajgenbaum DC, et al. Blood 2017; 129(12): 1646-1657, 2. Liu et al. Lancet Haematol 2016; 3(4): e163-75




for rare or low prevalence complex diseases









Zhang X, et al. Cancer Sci. 2018;109(1):199-206




Diseases (ERN EuroBloodNet)









Mukherjee S et al. Oral presentation at the virtual 62<sup>nd</sup> American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020.



 Network Hematological Diseases (ERN EuroBloodNet)

Network for rare or low prevalence complex diseases







# The annual prevalence of iMCD-related comorbidities during the 5 years following diagnosis (%)



\*Excludes lymphomas and myelomas.

Mukherjee S et al. Oral presentation at the virtual 62<sup>nd</sup> American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020.







- Malignant cells might be secreting IL-6 and other proinflammatory cytokines that cause the histopathological and clinical features of CD.
- Multicentric CD might be a premalignant state that can eventually transform.
- A common genetic mutation might make a patient susceptible to both CD and malignant diseases.
- Excessive cytokine release might promote malignant transformation.
- Treatment of CD eg, cytotoxic chemotherapy might amplify susceptibility to malignant disease.
- An unidentified virus might cause both CD and malignant disease.

Early and precise diagnosis of CD is essential to reduce morbidity and mortality!

Liu AY et al, Lancet Oncol 2016, 3:e163ff



**letwork** r rare or low prevalence omplex diseases









## **PATHOLOGY SUBSESSION**

1. Defining histopathologic features of CD


2. Histopathologic subtyping of CD

3. Possible mimics of CD









Ø Network

- Lymph node based disease (though extranodal involvement can be observed)
- Similar histologic features in different clinical variants/settings



### 1. Defining histopathologic features of CD



### International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

David C. Fajgenbaum,<sup>1</sup> Thomas S. Uldrick,<sup>2</sup> Adam Bagg,<sup>3</sup> Dale Frank,<sup>3</sup> David Wu,<sup>4</sup> Gordan Srkalovic,<sup>5</sup> David Simpson,<sup>6</sup> Amy Y. Liu,<sup>1</sup> David Menke,<sup>7</sup> Shanmuganathan Chandrakasan,<sup>8</sup> Mary Jo Lechowicz,<sup>8</sup> Raymond S. M. Wong,<sup>9</sup> Sheila Pierson,<sup>1</sup> Michele Paessler,<sup>10</sup> Jean-François Rossi,<sup>11</sup> Makoto Ide,<sup>12</sup> Jason Ruth,<sup>13</sup> Michael Croglio,<sup>14</sup> Alexander Suarez,<sup>1</sup> Vera Krymskaya,<sup>15</sup> Amy Chadburn,<sup>16</sup> Gisele Colleoni,<sup>17</sup> Sunita Nasta,<sup>18</sup> Raj Jayanthan,<sup>19</sup> Christopher S. Nabel,<sup>20</sup> Corey Cas Angela Dispenzieri,<sup>22</sup> Alexander Fosså,<sup>23</sup> Dermot Kelleher,<sup>24</sup> Razelle Kurzrock,<sup>25</sup> Peter Voorhees,<sup>26</sup> Ahmet Dogan,<sup>27</sup> Kazuyuki Yoshizaki,<sup>28</sup> Frits van Rhee,<sup>29</sup> Eric Oksenhendler,<sup>30</sup> Elaine S. Jaffe,<sup>2</sup> Kojo S. J. Elenitoba-Johnson,<sup>3</sup> and Megan S

Major criteria (need both)

- 1) Histopathologic lymph node features consistent with the iMCD spectrum
  - defined 5 primary lesions: 3 refer to features of GCs of the lymphoid follicle, 2 refer to features of the paracortical/interfollicular area
  - all cases show a preserved node architecture

2) Enlarged lymph nodes ( $\geq$  1 cm in short-axis diameter) in  $\geq$  2 lymph node stations spectrum


These are referred to idiopathic multicentric CD (all clinical subtypes), but with few mild differences they can apply to other clinical subtypes of mCD (HHV8, POEMS) and to uCD




 Network Hematological Diseases (ERN EuroBloodNet)


Reference Network for rare or low prevalence complex diseases













EUROPEAN HEMATOLOGY ASSOCIATION

### Follicular dendritic cell prominence



EuroBleedNet



Network Hematological Diseases (ERN EuroBloodNet)


EuroBleedNet

- These "primary" lesions are not specific in isolation
- Need of grading RGC: grade 2-3: most GC should be involved PC: grade 2-3: should be prominent and involve the whole lymph node


Fajgenbaum DC et al. Blood 2017;129:1646-1657.







### 2. Histopathologic subtyping of CD



- Cases easily classified as HyperV/HV or PC; others show a wider spectrum of combination of histologic features that do not allow clear attribution to either HyperV/HV or PC: Mixed
- Mixed concept: variably applied; some include the mixed variant within the spectrum of PC-CD
- These histologic subtypes can coexist, in serial concurrent or sequential biopsies from the same patient Fajgenbaum DC et al. *Blood* 2017;129:1646–1657; 2. Yu L et al. *Blood* 2017;129:1658–1668.; Wang W and Medeiros J. Surg Pathol. 2019; 12(3): 849-863. 3. Weisenburger DD. *Am J Surg Pathol.* 1988; 12(3): 176-81



Diseases (ERN EuroBloodNet)







### Match of clinical and histopathologic variants

- **UCD**: 90% HV or mixed, 10% PC
- MCD
  - **HHV8+ MCD:** Commonly PC (possibly with plasmablastic features)
  - **POEMS-MCD**: Commonly PC

•	iMCD*	<b>NOS</b> N=17	<b>IPL</b> N=9	<b>TAFRO</b> N=28
1	Plasmacytic	0	5	0
	Mixed	5	2	9
	Hypervascular	8	1	19
_	Hyaline Vascular	4	0	0



Network Hematological

Diseases (ERN EuroBloodNet)






\*From Pierson S – Rome – 16-17 Sept 2; Wu D, et al. Hematol Oncol Clin North Am. 2018; Wang W and Medeiros J. Surg Pathol. 2019; Dispenzieri A and Fajgenbaum DC. Blood. 2020;

### histological type and survival

- 2-year survival seemed to be worse in patients with the PC histopathological subtype (84% [95% CI, 72–99]) and mixed pathology (84% [95% CI, 73–97])<sup>1</sup>
  - Compared to those with hyaline vascular features (100% [100–100])





Network Hematological

**Network** for rare or low prevalence complex diseases


Diseases (ERN EuroBloodNet)







- Only 23%(18/79) patients had the same iMCD histopathologic subtype selected by all three groups of evaluators (Local site/Central pathology review/CDCN expert panel/Expanded panel
- Histopathology for diagnosing iMCD
- Histopathologic subtyping for clinical association, potential impact on survival, future relationship with biology
- currently insufficient evidence to use histopathologic subtype to guide treatment of iMCD
- Better subcategorize patients by clinicopathologic categories<sup>1</sup>
- Data from Accelerate, real life, Fajgenbaum 2020 AJH : no clear cut impact of histopathology subtyping on anti-IL6 response



white (unknown), grey (not CD), light blue (HV), blue (mixed), dark blue (PC). red (no match), green (Wetch): grey (Sot CD).




Fajgenbaum DC, et al. Am J Hematol. 2020; 95: 1553–1561.

3. Possible mimics of CD




Look for/exclude features suggestive of AI/AI diseases or pseudoneoplastic proliferations

Exclude neoplasms
>lymphomas, PCN
FDC sarcoma (mostly for UCD)



- Exclude HHV8-related CD (with IHC for LANA-1 marker)
- Exclude EBV infection (with ISH with EBER1/2 probe)





Network Hematological


Diseases (ERN EuroBloodNet)





Fajgenbaum DC et al. Blood 2017; Liu et al. Blood 2017





Five histological patterns are recognized: (1) multicentric Castleman's disease-like, (2) follicular hyperplasic, (3) interfollicular expansion, (4) progressive transformation of germinal center, and (5) nodal inflammatory pseudotumorlike. The specificity of these histologic changes in the absence of other evidence of IgG4-RD remains controversial Obliterative arteritis is often seen in pulmonary manifestations, particularly

solid lesions

iMCD patients 50% with elevated lgG4; PC-iMCD 25% have lgG4/lgG+ ratio >40%; 72.7% meet diagnostic criteria of lgG4-RD



③ Network

Hematological Diseases (ERN EuroBloodNet)


**Network** for rare or low prevalence complex diseases



Deshpande V. Semin Diagn Pathol. 2012




iMCD: Tissue IgA plasma cells more densely distributed





 Network for rare or low prevalence complex diseases
Network Hematological Diseases (ERN EuroBloodNet)





Sato et al. Mod Pathol 2009; Sun C et al. Clin Lab 2018; Manabe A et al Med Mol Morpohol




- HN and CD : one can co-occur, preceed or follow the other
- CD-like features can be induced by HN
- HN can itself mimic CD

Hematological Diseases (ERN EuroBloodNet)


HN diagnosed before/concurrently/shortly after iMCD may have been responsible for the cytokine storm that caused MCD-like histopathology (and clinical) features ---malignancies have to be excluded before diagnosing iMCD

HN diagnosed **more than one year after** iMCD diagnosis (with no evidence of the malignancy on the original **Eucliag** nostic lymph node or imaging) should not overturn Networ initial iMCD diagnosis





Faigenbaum et al. Blood 2017



MCD picture with monotypic plasmacells w/o monoclonal IgH

McAloon EJ. N Engl J Med. 1985, Maheswaran PR et al. Histopathology. 1991; Hsu SM et al. Am J Pathol. 1992; Saletti P et al. Ann Hematol. 1999; Molinie et al. Annales de Patologie 1994; Molinié V et al. Ann Pathol. 1995. Zarate-Osorno A, Arch Pathol Lab Med. 1994; Pina-Oviedo S et al Hum Pathol. 2017; Chapman J et al. Am J Surg Pathol. 2020; Siddiqi et al AJCP 2011; Xerri L et al. Virchows Arch. 2016; Al-Maghrabi J et al. Histopathology. 2006; Wu D et al. Hematol Oncol N Am 2018; Hsi E et al. American Journal of Clinical Pathology; Dispenzieri A. Blood Rev. 2007; Menke et al. AJCP 2001; Lin BT et al. Hum Pathol 1997; Radaszkiewicz T et al. Histopathology 1989



### **Diagnosis of Castleman disease**

**General aspects** 







Organomegaly: Enlarged liver or spleen **Generalized Lymphadenopathy:** Enlargement seen across multiple groups of lymph nodes

Flu-Like Symptoms: Fevers, night sweats, fatigue, and weight loss



Fluid Accumulation: Edema, ascites, and/or other symptoms of fluid overload

Laboratory abnormalities: Anemia, Hypoalbuminemia, elevated CRP levels



 Network Hematological Diseases (ERN EuroBloodNet)

for rare or low prevalence complex diseases



Fajgenbaum DC et al., Blood 2017; 129: 1646ff; Casper C, Br J Haematol 2005; 129: 3ff.





### Imaging

- A whole-body CT should be performed to distinguish unicentric from multicentric CD and to assess the number of enlarged lymph nodes
- An FDG-PET scan may help with identifying FDG-avid nodes for biopsy and with distinguishing CD from lymphoma

### **Excision biopsy**

- Histopathologic lymph nodes features must be consistent with CD spectrum
- It is suggested that the biopsy is reviewed by a pathologist who has CD expertise

### Laborytory testing


- Check hemoglobin, platelets, CRP, ESR, immunoglobulin, and albumin levels
- Asses renal function
- Check cytokine levels, including IL-6 and VEGF (if possible)











Fajgenbaum DC, et al. Blood. 2017;129(12):1646-1657. van Rhee F, et al. Blood. 2018:132(20):2115-2124.



Network Hematological Diseases (ERN EuroBloodNet)

for rare or low prevalence complex diseases





### I. Major Criteria (need both)

- 1. Histopathologic lymph node features consistent with the iMCD spectrum.
- 2. Enlarged lymph nodes (≥1 cm in short-axis diameter) in ≥2 lymph node stations

#### **II. Minor Criteria** (need ≥2 of 11 criteria with ≥1 laboratory criterion)

#### Laboratory

- 1. Elevated CRP
- 2. Anemia
- 3. Thrombocytopenia
- 4. Hypoalbuminemia
- 5. Renal dysfunction or proteinuria
- 6. Polyclonal hypergammaglobulinemia

#### Clinical

iropean

twork

complex diseases

 Network Hematological Diseases (ERN EuroBloodNet)

for rare or low prevalence

- 1. Constitutional symptoms: night sweats, fever, weight loss, or fatigue
- 2. Large spleen and/or liver
- 3. Fluid accumulation: edema, anasarca, ascites, or pleural effusion
- 4. Eruptive cherry hemangiomatosis or violaceous papules
- 5. Lymphocytic interstitial pneumonitis



Fajgenbaum D et al. Blood 2017; 129(12):1646–1657.





### Diagnosis is often delayed because of various factors:

- Biopsies are non-specific ("no signs of malignancies", "reactive")
- Some biopsies are non-diagnostic
- Symtoms can be episodic, or they appear to resolve
- Clinical experience is highly variable among hematologists
- Local experience is often limited
- There is a limited amount of guidelines

Multicentric CD is a rare but life-threatening disease!










- If diagnosis is not made by a pathologist who is experienced in hematology diagnosis, ask for a second reading from an expert.
- Take the time to discuss the case with a regional or national expert network; this will be helpful for diagnosis purposes, making treatment choices, and conducting clinical research.
- In case of any doubt, call the pathologist and discuss the case in depth together.











UROPEAN

CDCN researchers have massively contributed to the disease area which have led to

- a unique ICD-10 code for CD to allow physicians to easily treat CD and navigate insurance;
- the first set of international diagnostic and treatment guidelines for unicentric and multicentric CD;
- the first novel targeted treatment for iMCD in 25 years;
- the first clinical trial recruiting patients with treatment-refractory iMCD.







- 1. Castleman disease consists of a group of lymphoproliferative disorders that share a spectrum of histological features.
- 2. Avoiding time delay in diagnostic is essential, especially multicentric CD is not an indolent disease.
- 3. Diagnosis requires a close cooperation between clinician and pathologist.

# Thank you!





